[go: up one dir, main page]

WO1993019178A3 - Peptides useful for inducing tolerance - Google Patents

Peptides useful for inducing tolerance Download PDF

Info

Publication number
WO1993019178A3
WO1993019178A3 PCT/US1993/002462 US9302462W WO9319178A3 WO 1993019178 A3 WO1993019178 A3 WO 1993019178A3 US 9302462 W US9302462 W US 9302462W WO 9319178 A3 WO9319178 A3 WO 9319178A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
seq
peptides
inducing tolerance
peptides useful
Prior art date
Application number
PCT/US1993/002462
Other languages
French (fr)
Other versions
WO1993019178A2 (en
Inventor
Malcolm L Gefter
Richard D Garman
Julia L Greenstein
Mei-Chang Kuo
Thomas J Briner
Malcolm Morville
Original Assignee
Immunologic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunologic Pharma Corp filed Critical Immunologic Pharma Corp
Priority to JP5516715A priority Critical patent/JPH07505365A/en
Priority to CA2132873A priority patent/CA2132873C/en
Priority to EP93908385A priority patent/EP0672134A1/en
Priority to AU39226/93A priority patent/AU677954B2/en
Publication of WO1993019178A2 publication Critical patent/WO1993019178A2/en
Publication of WO1993019178A3 publication Critical patent/WO1993019178A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Physiology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)

Abstract

The present invention is based on the discovery that subcutaneous administration of a peptide comprising at least one T cell epitope of a protein allergen or other protein antigen results in T cell tolerance upon subsequent exposure to the allergen or other antigen. Peptides useful for inducing tolerance in a mammal, such as a human by subcutaneous administration or other routes of administration are within the scope of this invention. Such peptides include peptide X (SEQ ID NO: 7), peptide Y (SEQ ID NO: 8), peptide Z (SEQ ID NO: 9), peptide A (SEQ ID NO: 10), peptide B (SEQ ID NO: 11), peptide C (SEQ ID NO: 12), peptide D (SEQ ID NO: 13), and peptide E (SEQ ID NO: 14), each as shown in the figure. It is preferred that such peptides be administered in soluble form.
PCT/US1993/002462 1992-03-25 1993-03-25 Peptides useful for inducing tolerance WO1993019178A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP5516715A JPH07505365A (en) 1992-03-25 1993-03-25 Peptides useful for inducing resistance
CA2132873A CA2132873C (en) 1992-03-25 1993-03-25 Peptides useful for inducing tolerance
EP93908385A EP0672134A1 (en) 1992-03-25 1993-03-25 Peptides useful for inducing tolerance
AU39226/93A AU677954B2 (en) 1992-03-25 1993-03-25 Peptides useful for inducing tolerance

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US85731192A 1992-03-25 1992-03-25
US07/857,311 1992-03-25
US88471892A 1992-05-15 1992-05-15
US07/884,718 1992-05-15
US611693A 1993-01-15 1993-01-15
US08/006,116 1993-01-15

Publications (2)

Publication Number Publication Date
WO1993019178A2 WO1993019178A2 (en) 1993-09-30
WO1993019178A3 true WO1993019178A3 (en) 1993-11-25

Family

ID=27358042

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/002462 WO1993019178A2 (en) 1992-03-25 1993-03-25 Peptides useful for inducing tolerance

Country Status (7)

Country Link
EP (1) EP0672134A1 (en)
JP (1) JPH07505365A (en)
AU (1) AU677954B2 (en)
CA (1) CA2132873C (en)
IL (1) IL105153A (en)
MX (1) MX9301675A (en)
WO (1) WO1993019178A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6120769A (en) * 1989-11-03 2000-09-19 Immulogic Pharmaceutical Corporation Human T cell reactive feline protein (TRFP) isolated from house dust and uses therefor
US6019972A (en) * 1989-11-03 2000-02-01 Immulogic Pharmaceutical Corporation Peptides of human T cell reactive feline protein (TRFP)
NZ266739A (en) * 1993-06-02 1997-07-27 Tvw Telethon Inst Child Health Inducing immunologic tolerance by administering a cryptic peptide derived from the antigen der pi
US6759234B1 (en) * 1994-09-02 2004-07-06 Immulogic Pharmaceutical Corporation Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
JPH10504039A (en) * 1994-10-25 1998-04-14 イミユロジク・フアーマシユーチカル・コーポレーシヨン Compositions and treatments for multiple sclerosis
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
DE69739062D1 (en) 1996-03-21 2008-12-04 Circassia Ltd Use of cryptic peptides to induce immunological tolerance
JP3734040B2 (en) 1996-06-14 2006-01-11 明治乳業株式会社 T cell epitope peptide
US6780416B1 (en) 2000-02-18 2004-08-24 Ecole Polytechnique Federale De Lausanne Bee venom polypeptides and methods of use thereof
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
AT503690A1 (en) * 2006-06-09 2007-12-15 Biomay Ag HYPOALLERGENIC MOLECULES
HUE027237T2 (en) 2008-11-30 2016-10-28 Immusant Inc Preparations and methods for treating celiac disease
AU2014318889B2 (en) 2013-09-10 2020-02-20 Immusant, Inc. Dosage of a gluten peptide composition
AU2015323979A1 (en) 2014-09-29 2017-05-18 Immusant, Inc. Use of HLA genetic status to assess or select treatment of celiac disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006571A1 (en) * 1989-11-03 1991-05-16 Immulogic Pharmaceutical Corporation A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor
WO1992015613A1 (en) * 1991-02-28 1992-09-17 Immulogic Pharmaceutical Corporation Improved preparation of cat dander allergens for immunotherapeutic purposes and uses therefor
WO1993008280A1 (en) * 1991-10-16 1993-04-29 Immulogic Pharmaceutical Corporation Recombitope peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006571A1 (en) * 1989-11-03 1991-05-16 Immulogic Pharmaceutical Corporation A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor
WO1992015613A1 (en) * 1991-02-28 1992-09-17 Immulogic Pharmaceutical Corporation Improved preparation of cat dander allergens for immunotherapeutic purposes and uses therefor
WO1993008280A1 (en) * 1991-10-16 1993-04-29 Immulogic Pharmaceutical Corporation Recombitope peptides

Also Published As

Publication number Publication date
IL105153A (en) 1999-12-22
AU677954B2 (en) 1997-05-15
EP0672134A1 (en) 1995-09-20
CA2132873A1 (en) 1993-09-30
MX9301675A (en) 1993-12-01
IL105153A0 (en) 1993-07-08
WO1993019178A2 (en) 1993-09-30
JPH07505365A (en) 1995-06-15
AU3922693A (en) 1993-10-21
CA2132873C (en) 2012-10-16

Similar Documents

Publication Publication Date Title
WO1993019178A3 (en) Peptides useful for inducing tolerance
DK0590006T3 (en) Synthetic pulmonary surfactant peptides
CA2169635A1 (en) Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides
CA2025598A1 (en) Chimaeric hepadnavirus core antigen proteins
EP2145897A3 (en) Therapeutic methods and compositions based on serrate proteins and nucleic acids
ATE415173T1 (en) PAN DR BINDING PROTEINS TO INCREASE THE IMMUNE RESPONSE
ATE368053T1 (en) ANTIMICROBIAL PEPTIDES
EP0284587A3 (en) Synthetic peptide antigens for the detection of hiv-1 infection
EP0334244A3 (en) Bradykinin antagonist peptides
AU4826493A (en) Anti-feline immunodeficiency virus (fiv) vaccines
IL93397A (en) Pancreatic islet cell antigen protein or peptides, their preparation by molecular cloning, their use in the diagnosis of insulin dependent diabetes mellitus and pharmaceutical compositions comprising said antigens
EP0733071A4 (en) Antagonists to chaperonin 10
CA2083177A1 (en) Alveolar surfactant proteins
WO2002044197A3 (en) Cytokine receptor binding peptides
WO1993021321A3 (en) T CELL EPITOPES OF THE MAJOR ALLERGENS FROM $i(AMBROSIA ARTEMISIIFOLIA)
KR960702754A (en) VAGINAL PREPARATION CONTAINING PHYSIOLOGICALLY ACTIVE PEPTIDE containing physiologically active peptides
AU682638B2 (en) Peptide, bronchodilator and blood flow ameliorant
DE69313647D1 (en) SYNTHETIC PEPTIDES AS LUNG SURFACTANTS WITH COVALENT-TIED ANTIOXIDANTS
CA2128407A1 (en) Synthetic peptides for a rubella vaccine
CA2139571A1 (en) Interferon receptor binding peptides
DE69315849D1 (en) PEPTIDE AS A LUNG SURFACTANT AND THERAPEUTICALLY ACTIVE MIXTURES
CA2057612A1 (en) Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof
AU4712993A (en) New peptides, antibodies raised against peptides and means for blocking said antibodies, application as medicaments, pharmaceutical compositions and utilization methods
CA2163212A1 (en) Therapeutic compounds
EP0317279A3 (en) Peptides for use in the purification of factor viii

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA FI HU JP KP KR NO NZ PT

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA FI HU JP KP KR NO NZ PT

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2132873

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1993908385

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993908385

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993908385

Country of ref document: EP